Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
about
The notch ligand jagged-1 represents a novel growth factor of human hematopoietic stem cellsA congenital mutation of the novel gene LRRC8 causes agammaglobulinemia in humansIn vivo correction of ZAP-70 immunodeficiency by intrathymic gene transferCharged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregationMedical immunology: a new journal for a new subspecialty.Genetic modification of somatic stem cells. The progress, problems and prospects of a new therapeutic technologyDrug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeuticsCorrection of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapyLentiviral vectors in gene therapy: their current status and future potentialZinc-finger nuclease-induced gene repair with oligodeoxynucleotides: wanted and unwanted target locus modificationsLentiviral vector gene therapy: effective and safe?Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cellsGene therapy for severe combined immunodeficiency: are we there yet?Correction of canine X-linked severe combined immunodeficiency by in vivo retroviral gene therapyThe molecular pathology of primary immunodeficienciesIn Vivo Noninvasive Imaging for Gene TherapyEarly steps of retrovirus replicative cycleSuccess for gene therapy: render unto Caesar that which is Caesar'sIntegration of retroviruses: a fine balance between efficiency and dangerMulti-OMICs and Genome Editing Perspectives on Liver Cancer Signaling NetworksAdvances of gene therapy for primary immunodeficienciesMicroneedles As a Delivery System for Gene TherapyProduction of lentiviral vectorsRecent advances of biomaterials in biotherapyProduction and clinical development of nanoparticles for gene deliveryRecent advances in treatment of severe primary immunodeficienciesGenome-editing Technologies for Gene and Cell TherapyMegakaryocyte- and megakaryocyte precursor-related gene therapiesTowards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapyCell Penetrating Peptide Conjugated Chitosan for Enhanced Delivery of Nucleic AcidHuman genetic basis of interindividual variability in the course of infectionCell-based therapy technology classifications and translational challengesMultifunctional facets of retrovirus integraseA short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiformeHematopoietic stem cell gene therapy:assessing the relevance of preclinical modelsRetroviral integrations in gene therapy trialsGene therapy for skin diseasesGene doping: gene delivery for olympic victoryGene therapy: light is finally in the tunnelGene therapy on the move
P2860
Q24290490-B4DA2FF0-9159-4F66-8E84-E85306EA2CC5Q24301360-707C94FE-4E9B-4182-9B35-890252C86590Q24532255-C676FD4B-2B3F-4719-96DF-7F1F8131D343Q24537755-98BD1555-85C2-4A4D-B766-3B33ED02DA3DQ24538980-98633F86-1608-43BB-B6F4-9BE267BDC9D1Q24595921-F355AACA-3C0E-4088-9032-E59F7BF35E1CQ24616751-E2C3B4AB-B03D-4554-BE05-A6117C10795AQ24621941-2E9A3BF5-7D64-4831-961B-2DDA192AE850Q24629462-9C0D5D47-844C-4283-8BFE-0C395907BA57Q24630071-364CD068-2612-435C-99DD-84FF5F544CB7Q24630888-C210CAED-0721-4B0B-8A8A-570E944DFE98Q24644026-0C80436C-904E-442A-8D16-6DC2D40F635AQ24680426-E854B6D7-86D6-45B1-90DD-C9763FD3848DQ24685725-0061D0E7-C6D8-44B0-BF9E-83372C750C15Q24685932-E75CDF99-B3BE-4024-B035-D2D8C52C515DQ24790997-C80BB976-E974-4D53-9761-F9FC73EF1D68Q24792862-ED1F404F-7FA0-4E97-89E6-17ACC87D3ABEQ24797320-F7654173-B087-4FCC-A4E1-E5756F0772D6Q24809161-1D1BA93B-B85C-4537-B5FA-D5A11E57F929Q26741086-783744B9-4E67-4F59-95C4-9F47D94161A0Q26742031-82180E40-3092-4C75-A090-C3FF8B4294F7Q26746026-AB4E54A2-30CC-4BB0-9A42-75A66F6195B5Q26750586-44743FB5-7DCE-45CB-B0DD-86DBE8A92ED2Q26752054-FED85A14-44D7-4961-AE70-D969AA75BD40Q26752803-362BEA5B-3326-428E-8462-DCB208976C22Q26766170-054F8594-1F73-4DD0-86A3-8AE58924D20EQ26769662-60A836F5-48FB-450E-BFEB-448E0F39ECE6Q26770867-A647B130-F2C3-4E86-B993-B553EC03236DQ26771159-FBE8CB8A-CEAC-4AF0-93B1-C530DD73F933Q26774462-F32A22E6-99C9-4AD9-AE7D-193402F61A16Q26775894-8B93391A-9B1B-497D-B843-4A508EF44856Q26785346-612BE673-9FE3-4015-A9A5-8041CA136C3BQ26795766-C739EC2D-8CDD-48A4-B6D9-9D047BF6F3C2Q26849375-119167EC-EBFE-4B8F-BE42-A7A857A0C585Q26859147-C387D4F1-365B-4CA7-B86E-0503A11791F7Q26991660-09F1A281-01C6-4EAF-ACBF-CE3AA171CB71Q26994703-AE07BD5B-7392-4822-AF7B-718C137FFFF2Q26995443-C92F43BF-0881-486E-9745-709587E6BF10Q27000091-CBF45910-02BF-4FEA-BBF0-37973785E33AQ27007012-57E10D7D-488B-4D0E-8873-C62D5B20328F
P2860
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
@ast
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
@en
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
@nl
type
label
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
@ast
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
@en
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
@nl
prefLabel
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
@ast
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
@en
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
@nl
P2093
P3181
P1433
P1476
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
@en
P2093
G de Saint Basile
J L Casanova
P304
P3181
P356
10.1126/SCIENCE.288.5466.669
P407
P577
2000-04-28T00:00:00Z